Only the study by Lantazi et al. analyzed the efficacy of targeted therapy in NM and SSM patients and demonstrated a decreased survival for BRAF-mutated NM as compared with BRAF-mutated SSM patients, and histologic subtype NM in the multivariate analysis was independently associated with a decreased survival. The gene discussed is BRAF; the disease is nemaline myopathy.